Get the Stockscreener App
1.74
0.00%
0.00
After Hours:
1.70
-0.04
-2.30%
Biorestorative Therapies Inc stock is traded at $1.74, with a volume of 14,051.
It is up +0.00% in the last 24 hours and up +6.10% over the past month.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.
See More
Previous Close:
$1.74
Open:
$1.7
24h Volume:
14,051
Relative Volume:
0.34
Market Cap:
$12.04M
Revenue:
$149.50K
Net Income/Loss:
$-6.96M
P/E Ratio:
-0.3655
EPS:
-4.76
Net Cash Flow:
$-6.37M
1W Performance:
-3.87%
1M Performance:
+6.10%
6M Performance:
+26.09%
1Y Performance:
-2.79%
1-Day Range:
$1.70
$1.79
1-Week Range:
$1.67
$1.8768
52-Week Range:
$1.03
$3.6699
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies (OTCMKTS:BRTXQ) Sets New 1-Year High at $1.79 - Defense World
BioRestorative Therapies, Inc. (NASDAQ:BRTX) Short Interest Update - Defense World
BioRestorative Therapies (OTCMKTS:BRTXQ) Reaches New 12-Month High at $1.91 - Defense World
BioRestorative Therapies expands stock incentive plan - Investing.com
Acadian Asset Management LLC Sells 107,112 Shares of BioNTech SE (NASDAQ:BNTX) - MarketBeat
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
Beasley Broadcast Group Approves Reverse Stock Split - RADIO ONLINE
BioLife Solutions (NASDAQ:BLFS) Stock Price Up 5.8% - MarketBeat
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September. - Barron's
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Bought by Meiji Yasuda Life Insurance Co - Defense World
Mutual of America Capital Management LLC Purchases Shares of 108,713 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Beasley Does a Reverse Stock Split - Radio World
Biomarin Pharmaceutical Inc. [BMRN] Shares Fall Approximately -19.71% Over the Year - Knox Daily
Daily Market Movement: BioNTech SE ADR (BNTX) Sees a -7.29 Decrease, Closing at 115.62 - The Dwinnex
Royal Bank of Canada Reiterates Outperform Rating for Biogen (NASDAQ:BIIB) - MarketBeat
BioLife Solutions (NASDAQ:BLFS) Shares Down 2% - Defense World
Beasley Broadcast Group’s Reverse Stock Split: What Shareholders Need to Know - TALKERS magazine
Massachusetts Financial Services Co. MA Boosts Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) - Defense World
Banzai announces 1-for-50 reverse stock split - TipRanks
Beasley Media Group Implementing Reverse Stock Split. - Insideradio.com
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $26.19 - Defense World
Bio-Rad Laboratories, Inc. (NYSE:BIO) Expected to Post Q3 2024 Earnings of $2.13 Per Share - MarketBeat
BioRestorative Therapies’ IFATS 2024 Presentation to - GlobeNewswire
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs - StockTitan
Beyond Inc [BYON] stock for 97,352 USD was sold by Nettles William Benjamin JR - Knox Daily
BioNTech (NASDAQ:BNTX) Given New $131.00 Price Target at UBS Group - Defense World
Bosnian businessman launches buyout bid for Bihacka Pivovara - SeeNews
Bridger Aerospace group's interim CEO sells shares worth over $66k - Investing.com India
BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells $17,007.12 in Stock - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India
FDA grants Breakthrough Therapy to oral infigratinib for children with achondroplasia - Contemporary Pediatrics
Jefferies upgrades BioNTech SE ADR (BNTX) rating to a Buy - Knox Daily
UBS Group Boosts BioNTech (NASDAQ:BNTX) Price Target to $131.00 - MarketBeat
Texas Permanent School Fund Corp Invests $2.19 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Benitec Biopharma Announces Late Breaking Oral Abstract - GlobeNewswire
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients - GlobeNewswire
BriaCell Announces FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients - StockTitan
Bokf Na Acquires Shares of 375 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - Defense World
Positive Ascendis data threatens BioMarin's lead in achondroplasia - The Pharma Letter
BioMarin Pharmaceutical (NASDAQ:BMRN) Given New $87.00 Price Target at Stifel Nicolaus - Defense World
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Cut to $115.00 by Analysts at Bank of America - Defense World
BridgeBio Pharma (NASDAQ:BBIO) Stock Rating Reaffirmed by HC Wainwright - Defense World
Cantor Fitzgerald Reiterates “Overweight” Rating for BridgeBio Pharma (NASDAQ:BBIO) - Defense World
Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia
BioNTech SE ADR rises Tuesday, outperforms market - MarketWatch
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery - Investor's Business Daily
Bham business receives $2.8M for brain aneurysm technology - The Business Journals
Goodwin Advises Bicara’s $362 Million Upsized Initial Public Offering - Goodwin Procter
BioNTech SE ADR (NASDAQ:BNTX) Upgraded By JPMorgan - FXDailyReport.com
Ascendis trial data piles pressure on BioMarin - BioPharma Dive
FDA Grants Breakthrough Status to Achondroplasia Drug By Investing.com - Investing.com Canada
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):